Gain Therapeutics (NASDAQ:GANX) Coverage Initiated by Analysts at Scotiabank

Scotiabank started coverage on shares of Gain Therapeutics (NASDAQ:GANX) in a research report report published on Friday morning, Marketbeat reports. The firm issued a sector outperform rating and a $12.00 target price on the stock.

A number of other analysts have also commented on GANX. Roth Mkm reaffirmed a “buy” rating and issued a $7.00 price target on shares of Gain Therapeutics in a research note on Tuesday, December 24th. Roth Capital raised Gain Therapeutics to a “strong-buy” rating in a research note on Thursday, December 5th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 price target on shares of Gain Therapeutics in a research note on Monday, November 25th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $8.20.

Gain Therapeutics Stock Up 4.4 %

Shares of Gain Therapeutics stock opened at $1.88 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.99 and a current ratio of 2.99. Gain Therapeutics has a 52-week low of $0.89 and a 52-week high of $4.80. The stock has a market capitalization of $49.87 million, a price-to-earnings ratio of -1.71 and a beta of 0.14. The company’s 50 day moving average price is $2.24 and its 200-day moving average price is $1.95.

Hedge Funds Weigh In On Gain Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sprott Inc. purchased a new position in Gain Therapeutics during the fourth quarter valued at $30,000. Benedict Financial Advisors Inc. purchased a new position in Gain Therapeutics during the fourth quarter valued at $35,000. Bridgeway Capital Management LLC purchased a new position in Gain Therapeutics during the fourth quarter valued at $65,000. Northern Trust Corp lifted its position in Gain Therapeutics by 88.2% during the fourth quarter. Northern Trust Corp now owns 84,586 shares of the company’s stock valued at $183,000 after buying an additional 39,642 shares during the period. Finally, Marshall Wace LLP purchased a new position in Gain Therapeutics during the fourth quarter valued at $198,000. Hedge funds and other institutional investors own 11.97% of the company’s stock.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.